{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:56:08Z","timestamp":1791834968430,"version":"4.3.4"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T00:00:00Z","timestamp":1387152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      We aimed to assess the prevalence of impulse control disorders (\n                      <jats:styled-content style=\"fixed-case\">ICD<\/jats:styled-content>\n                      s) in patients with prolactin\u2010secreting adenomas treated with dopamine agonists (\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      s), to identify associated factors and to compare it with a group of patients with nonfunctioning pituitary adenoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects, Design and Measurement<\/jats:title>\n                    <jats:p>\n                      In a postal survey, 77 patients from Group A (patients with prolactinomas and present or past use of\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      s) and 70 patients from Group B (patients with nonfunctioning pituitary adenoma and no history of\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      therapy) responded to a questionnaire on compulsive shopping, pathologic gambling, hypersexuality and punding. Associated clinical information was obtained through the survey and review of medical electronic records.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The total\n                      <jats:styled-content style=\"fixed-case\">ICD<\/jats:styled-content>\n                      prevalence was 24\u00b768% in Group A and 17\u00b71% in Group B (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00\u00b731). Group A had an increased rate of hypersexuality (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00\u00b703). Subgroup analysis revealed that men in Group A had a significantly increased frequency of total\n                      <jats:styled-content style=\"fixed-case\">ICD<\/jats:styled-content>\n                      s when compared with men in Group B (27\u00b77\n                      <jats:italic>vs<\/jats:italic>\n                      3\u00b77%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00\u00b701). No differences in rates of total\n                      <jats:styled-content style=\"fixed-case\">ICD<\/jats:styled-content>\n                      s were found between women of Groups A and B (20\n                      <jats:italic>vs<\/jats:italic>\n                      25\u00b76%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00\u00b778). No association with type, dose or duration of treatment with\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      was noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Males with prolactinomas treated with\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      s were 9\u00b79 times more likely to develop an\n                      <jats:styled-content style=\"fixed-case\">ICD<\/jats:styled-content>\n                      than their counterparts with nonfunctioning pituitary adenomas. Until prospective studies on the relationship of\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      use in patients with prolactinoma and\n                      <jats:styled-content style=\"fixed-case\">ICD<\/jats:styled-content>\n                      s are available, the authors propose that patients with prolactinoma be forewarned of possible\n                      <jats:styled-content style=\"fixed-case\">ICD<\/jats:styled-content>\n                      development with\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cen.12375","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T06:45:17Z","timestamp":1385448317000},"page":"863-868","source":"Crossref","is-referenced-by-count":123,"title":["Impulse control disorders in patients with dopamine agonist\u2010treated prolactinomas and nonfunctioning pituitary adenomas: a case\u2013control study"],"prefix":"10.1111","volume":"80","author":[{"given":"Irina","family":"Bancos","sequence":"first","affiliation":[{"name":"Division of Endocrinology Department of Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Nannenga","sequence":"additional","affiliation":[{"name":"Division of Endocrinology Holston Medical Group Kingsport TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Bostwick","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Silber","sequence":"additional","affiliation":[{"name":"Department of Neurology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Erickson","sequence":"additional","affiliation":[{"name":"Division of Endocrinology Department of Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd B.","family":"Nippoldt","sequence":"additional","affiliation":[{"name":"Division of Endocrinology Department of Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000076478.45005.EC"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000218206.20920.4d"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.7.969"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60538-7"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2005.06.005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000238503.20816.13"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20757"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20045"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.129015"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20046"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.8.1089"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60846-X"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2009.tb02289.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.19.4.473"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2012.10.002"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3182281b2f"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.144.9.1184"},{"key":"e_1_2_6_20_1","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case\u2010control study","volume":"33","author":"Cornelius J.R.","year":"2010","journal-title":"Sleep"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbp.2012.03.001"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335996"},{"key":"e_1_2_6_23_1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/WNF.0b013e31820d6699","article-title":"The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome","volume":"34","author":"Dang D.","year":"2011","journal-title":"Clinical Neuropharmacology"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.12.1358"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-11-117"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen.12375","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.12375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T22:54:41Z","timestamp":1696287281000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.12375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,16]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1111\/cen.12375"],"URL":"https:\/\/doi.org\/10.1111\/cen.12375","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,16]]}}}